Immunotherapy for Bladder Cancer

Immunotherapy for Bladder Cancer: Review

It is nearly 40 years since Bacillus Calmette–Guérin (BCG) was first used as an immunotherapy to treat superficial bladder cancer. Despite its limitations, to date it has not been surpassed by any other treatment.
The immune response to BCG can be summarized as follows: infection of urothelial and bladder tumor cells by BCG results in internalization of BCG, which increases the expression of antigen -presenting molecules. This induces an immune response via cytokine release. Th1 cytokines (IL-2, tumor necrosis factor, IL-12, and IFN-γ) and Th2 cytokines (IL-4, IL-5, IL-6, and IL-10) along with IL-8 and IL-17 are all implicated. This complex immune cascade induces antitumor activity mediated by cytotoxic T lymphocytes, natural killer cells, neutrophils, and macrophages.
There is now a large body of evidence demonstrating the superior efficacy of BCG in the treatment of bladder cancer when compared with TUR alone or TUR and chemotherapy. The European Association of Urology (EAU) guidelines on non-muscle invasive bladder cancer in 2013 report a total of five meta-analyses to substantiate this claim. In addition, there have been individual randomized controlled trials comparing BCG with epirubicin and IFN, mitomycin C, and epirubicin alone, all of which showed BCG to be the best agent with respect to preventing recurrence.
More immunotherapy treatments are under research now, which may show advantages over BCG, or supplement the limitations of BCG.

Immunotherapy for Bladder Cancer: Reference

Fuge O et al. Immunotherapy for bladder cancer. Research and Reports in Urology. 2015;7:65-79.
Morales A et al. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183.

Immunotherapy
What is Immunotherapy
Cancer Immunotherapy
What is Immunotherapy for Cancer
Monoclonal Antibody for Cancer Immunotherapy
Immune Checkpoint
Vaccines for Cancer Immunotherapy
Immune Modulation for Cancer Immunotherapy
Oncolytic Viruses for Cancer Immunotherapy
Adoptive Immunotherapy for Cancer+
- What is Adoptive Immunotherapy for Cancer
- Tumor-Infiltrating Lymphocytes (TILs) for Cancer Immunotherapy
- Chimeric Antigen Receptor (CAR) T-cell for Cancer Immunotherapy
- Epstein–Barr Virus (EBV)-Specific T Cells for Cancer Immunotherapy
Immunotherapy for Lung Cancer
Immunotherapy for Melanoma
Cancer Immunotherapy for Breast Cancer
Immunotherapy for Prostate Cancer
Immunotherapy for Pancreatic Cancer
Immunotherapy for Ovavian Cancer
Immunotherapy for Colon Cancer
Immunotherapy for Bladder Cancer
Immunotherapy for Liver Cancer
Immunotherapy for Kidney Cancer
Immunotherapy for Brain Cancer
Immunotherapy for Esophageal Cancer
Immunotherapy for Gastric Cancer
Cancer Immunotherapy for Leukemia
Cancer Immunotherapy Clinical Trials
Cancer Immunotherapy Companies
Immunotherapy Drugs for Cancer
Breakthrough of Cancer Immunotherapy
Side Effects of Immunotherapy for Cancer
Cancer Immuotherapy Conference
Cancer Immuotherapy Related Molecules+
- Immune Checkpoint Targets
- Monoclonal Antibody Targets for Cancer Immunotherapy
- Vaccine Antigens for Cancer Immunotherapy
- Cytokines for Cancer Immunotherapy
- Tumor Antigens for Cancer Immunotherapy
Allergy Immunotherapy
Autoimmune Diseases Immunotherapy
Immunotherapy Related Molecules
Sublingual Immunotherapy
Side Effects of Immunotherapy
Immunotherapy Drugs
Adoptive Immunotherapy
Journal of Immunotherapy
Immunotherapy Conference